Positron Emission Mammography and Standard Mammography in Women With Dense Breast Tissue or Who Are at High Risk of Breast Cancer



Status:Archived
Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:February 2009
End Date:January 2013

Use our guide to learn which trials are right for you!

Impact of Dedicated Breast PET Imaging vs. Conventional Two-View Digital Mammography on Recall Rates and Cancer Detection as a Screening Examination in Underserved Women


RATIONALE: Screening tests may help doctors find cancer cells early and plan better
treatment for breast cancer. It is not yet known whether positron emission mammography is
more effective than standard mammography in finding breast tumors.

PURPOSE: This phase III trial is studying positron emission mammography to see how well it
works compared with standard mammography in women with dense breast tissue or who are at
high risk of breast cancer.


OBJECTIVES:

- To install the breast PET system and to test and ensure its compliance with all
regulatory agencies including the ACR and FDA.

- To measure and compare the number of call-backs for positron emission mammography (PEM)
imaging and conventional mammography, and to calculate the number of true positive and
false positive exams for mammograms and PEM imagining using pathologic results and
yearly follow-up mammogram results (cancer detection rate) in women with dense breast
tissue or at high risk for breast cancer.

- To measure and compare patient satisfaction for both conventional mammography and PEM
in terms of comfort and pain.

- To measure and compare the cost effectiveness with conventional mammography vs PEM by
examining cost, examination time, and radiologist reading time.

OUTLINE: Patients undergo a conventional two-view mammogram and positron emission
mammography (PEM). Immediately following treatment, patients complete a questionnaire on
their satisfaction with the standard mammogram and the PEM.

After completion of study treatment, patients are followed annually.


We found this trial at
1
site
72 East Concord St.
Boston, Massachusetts 02118
617-638-4173
Boston University Cancer Research Center
?
mi
from
Boston, MA
Click here to add this to my saved trials